Mirum Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Mirum Pharmaceuticals, Inc. (MIRM) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$67.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$67.23M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$790.15M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $2.90M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$5.86M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$87.94M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$163.41M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$136.58M.
- Mirum Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$83.99M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$67.23M 10-Q · filed 2026-08-05 | -$857.38M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$790.15M 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | $2.90M 10-Q · filed 2025-11-04 | -$2.96M derived: sum of 2 quarters · filed 2026-08-05 | -$17.63M 10-Q · filed 2025-11-04 | -$41.42M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$5.86M 10-Q · filed 2026-08-05 | -$20.54M 10-Q · filed 2026-08-05 | -$44.33M derived: sum of 3 quarters · filed 2026-08-05 | -$58.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$14.68M 10-Q · filed 2026-05-06 | -$38.47M derived: sum of 2 quarters · filed 2026-05-06 | -$52.70M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$23.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$38.02M derived: sum of 2 quarters · filed 2025-11-04 | -$87.94M 10-K · filed 2025-02-26 | |
| 2024-09-30 | -$14.23M 10-Q · filed 2025-11-04 | -$64.15M 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | -$163.41M 10-K · filed 2025-02-26 | |||
| 2022-12-31 | -$37.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$72.90M derived: sum of 2 quarters · filed 2025-02-26 | -$100.02M derived: sum of 3 quarters · filed 2025-02-26 | -$136.58M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$35.71M 10-Q · filed 2023-11-02 | -$62.83M derived: sum of 2 quarters · filed 2023-11-02 | -$99.38M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$27.12M 10-Q · filed 2023-08-07 | -$63.73M 10-Q · filed 2023-08-07 | ||
| 2021-12-31 | -$83.99M 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |